138 related articles for article (PubMed ID: 35500728)
1. Design and synthesis of endocannabinoid enzyme inhibitors for ocular indications.
Fulp A; Bingham S; Fisler B; Kho F; Kim J; Kim SJ; Martin T; Mims B; Reji Thomas K; Roe G; Spiotta J; Young J; Lazenka M
Bioorg Med Chem Lett; 2022 Jul; 68():128763. PubMed ID: 35500728
[TBL] [Abstract][Full Text] [Related]
2. A comparison of novel, selective fatty acid amide hydrolase (FAAH), monoacyglycerol lipase (MAGL) or dual FAAH/MAGL inhibitors to suppress acute and anticipatory nausea in rat models.
Parker LA; Limebeer CL; Rock EM; Sticht MA; Ward J; Turvey G; Benchama O; Rajarshi G; Wood JT; Alapafuja SO; Makriyannis A
Psychopharmacology (Berl); 2016 Jun; 233(12):2265-75. PubMed ID: 27048155
[TBL] [Abstract][Full Text] [Related]
3. Distinct Activity of Endocannabinoid-Hydrolyzing Enzymes MAGL and FAAH in Key Regions of Peripheral and Central Nervous System Implicated in Migraine.
Della Pietra A; Giniatullin R; Savinainen JR
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33530477
[TBL] [Abstract][Full Text] [Related]
4. Endocannabinoid metabolism inhibition ameliorates ovalbumin-induced allergic airway inflammation and hyperreactivity in Guinea pigs.
Abohalaka R; Karaman Y; Recber T; Onder SC; Nemutlu E; Bozkurt TE
Life Sci; 2022 Oct; 306():120808. PubMed ID: 35843343
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of carbamate derivatives as fatty acid amide hydrolase and monoacylglycerol lipase inhibitors.
Jaiswal S; Gupta G; Ayyannan SR
Arch Pharm (Weinheim); 2022 Nov; 355(11):e2200081. PubMed ID: 35924298
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of dual fatty acid amide hydrolase-monoacylglycerol lipase inhibition and antinociceptive activities of 4-methylsulfonylaniline-derived semicarbazones.
Jaiswal S; Akhilesh ; Uniyal A; Tiwari V; Raja Ayyannan S
Bioorg Med Chem; 2022 Apr; 60():116698. PubMed ID: 35296453
[TBL] [Abstract][Full Text] [Related]
7. Piperazine and piperidine carboxamides and carbamates as inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL).
Korhonen J; Kuusisto A; van Bruchem J; Patel JZ; Laitinen T; Navia-Paldanius D; Laitinen JT; Savinainen JR; Parkkari T; Nevalainen TJ
Bioorg Med Chem; 2014 Dec; 22(23):6694-6705. PubMed ID: 25282655
[TBL] [Abstract][Full Text] [Related]
8. 1,3,4-Oxadiazol-2-ones as fatty-acid amide hydrolase and monoacylglycerol lipase inhibitors: Synthesis, in vitro evaluation and insight into potency and selectivity determinants by molecular modelling.
Käsnänen H; Minkkilä A; Taupila S; Patel JZ; Parkkari T; Lahtela-Kakkonen M; Saario SM; Nevalainen T; Poso A
Eur J Pharm Sci; 2013 Jun; 49(3):423-33. PubMed ID: 23557840
[TBL] [Abstract][Full Text] [Related]
9. Potent dual MAGL/FAAH inhibitor AKU-005 engages endocannabinoids to diminish meningeal nociception implicated in migraine pain.
Della Pietra A; Krivoshein G; Ivanov K; Giniatullina R; Jyrkkänen HK; Leinonen V; Lehtonen M; van den Maagdenberg AMJM; Savinainen J; Giniatullin R
J Headache Pain; 2023 Apr; 24(1):38. PubMed ID: 37038131
[TBL] [Abstract][Full Text] [Related]
10. Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice.
Ramesh D; Gamage TF; Vanuytsel T; Owens RA; Abdullah RA; Niphakis MJ; Shea-Donohue T; Cravatt BF; Lichtman AH
Neuropsychopharmacology; 2013 May; 38(6):1039-49. PubMed ID: 23303065
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the endocannabinoid-regulating enzyme monoacylglycerol lipase elicits a CB
Owens RA; Mustafa MA; Ignatowska-Jankowska BM; Damaj MI; Beardsley PM; Wiley JL; Niphakis MJ; Cravatt BF; Lichtman AH
Neuropharmacology; 2017 Oct; 125():80-86. PubMed ID: 28673548
[TBL] [Abstract][Full Text] [Related]
12. (4-Phenoxyphenyl)tetrazolecarboxamides and related compounds as dual inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL).
Holtfrerich A; Hanekamp W; Lehr M
Eur J Med Chem; 2013 May; 63():64-75. PubMed ID: 23455058
[TBL] [Abstract][Full Text] [Related]
13. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo.
Long JZ; Nomura DK; Vann RE; Walentiny DM; Booker L; Jin X; Burston JJ; Sim-Selley LJ; Lichtman AH; Wiley JL; Cravatt BF
Proc Natl Acad Sci U S A; 2009 Dec; 106(48):20270-5. PubMed ID: 19918051
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Isatin-Based Carbohydrazones as Potential Dual Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase.
Jaiswal S; Ayyannan SR
ChemMedChem; 2022 Jan; 17(1):e202100559. PubMed ID: 34637598
[TBL] [Abstract][Full Text] [Related]
15. Systemic and spinal administration of FAAH, MAGL inhibitors and dual FAAH/MAGL inhibitors produce antipruritic effect in mice.
Yesilyurt O; Cayirli M; Sakin YS; Seyrek M; Akar A; Dogrul A
Arch Dermatol Res; 2016 Jul; 308(5):335-45. PubMed ID: 27126057
[TBL] [Abstract][Full Text] [Related]
16. Hexafluoroisopropyl Carbamates as Selective MAGL and Dual MAGL/FAAH Inhibitors: Biochemical and Physicochemical Properties.
Barth M; Rudolph S; Kampschulze J; Meyer Zu Vilsendorf I; Hanekamp W; Mulac D; Langer K; Lehr M
ChemMedChem; 2022 May; 17(9):e202100757. PubMed ID: 35072346
[TBL] [Abstract][Full Text] [Related]
17. The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease?
Bajaj S; Jain S; Vyas P; Bawa S; Vohora D
Brain Res Bull; 2021 Sep; 174():305-322. PubMed ID: 34217798
[TBL] [Abstract][Full Text] [Related]
18. Development and characterization of endocannabinoid hydrolases FAAH and MAGL inhibitors bearing a benzotriazol-1-yl carboxamide scaffold.
Morera L; Labar G; Ortar G; Lambert DM
Bioorg Med Chem; 2012 Nov; 20(21):6260-75. PubMed ID: 23036333
[TBL] [Abstract][Full Text] [Related]
19. Organophosphate agents induce plasma hypertriglyceridemia in mouse via single or dual inhibition of the endocannabinoid hydrolyzing enzyme(s).
Suzuki H; Ito Y; Noro Y; Koketsu M; Kamijima M; Tomizawa M
Toxicol Lett; 2014 Feb; 225(1):153-7. PubMed ID: 24361246
[TBL] [Abstract][Full Text] [Related]
20. Δ9-tetrahydrocannabinol and endocannabinoid degradative enzyme inhibitors attenuate intracranial self-stimulation in mice.
Wiebelhaus JM; Grim TW; Owens RA; Lazenka MF; Sim-Selley LJ; Abdullah RA; Niphakis MJ; Vann RE; Cravatt BF; Wiley JL; Negus SS; Lichtman AH
J Pharmacol Exp Ther; 2015 Feb; 352(2):195-207. PubMed ID: 25398241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
